ArticleMarine drugs2021
In Vitro Bioactivity of Astaxanthin and Peptides from Hydrolisates of Shrimp (
Article in Marine drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 48 citations in OpenAlex.
- Valorization of Hemp, Shrimp and Blue Crab Co-Products as Novel Culture Media Ingredients to Improve Protein Quality and Antioxidant Capacity of Cultured Meat in Cell-Based Food Applications.Foods (Basel, Switzerland) · 2026Article
- Photoprotective and Anti-Melanogenic Effects of Supercritical Fluids Extract fromMarine drugs · 2026Article
- Valorization of Blue Crab (Animals : an open access journal from MDPI · 2025Article
- Production Methods, Biological Activity and Potential Application Prospects of Astaxanthin.Foods (Basel, Switzerland) · 2025Review
- Bioactivity of Marine-Derived Peptides and Proteins: A Review.Marine drugs · 2025Review
- Valorization of the Invasive Blue Crabs (Marine drugs · 2024Review
- Statistical Tools to Optimize the Recovery of Bioactive Compounds from Marine Byproducts.Marine drugs · 2024Review
- Shrimp Waste Upcycling: Unveiling the Potential of Polysaccharides, Proteins, Carotenoids, and Fatty Acids with Emphasis on Extraction Techniques and Bioactive Properties.Marine drugs · 2024Review
- Efficient recovery of functional biomolecules from shrimp (Current research in food science · 2024Article
- A review on the processing of functional proteins or peptides derived from fish by-products and their industrial applications.Heliyon · 2023Review
- Marine Sources of DHA-Rich Phospholipids with Anti-Alzheimer Effect.Marine drugs · 2022Review
- Recent findings on the cellular and molecular mechanisms of action of novel food-derived antihypertensive peptides.Food chemistry. Molecular sciences · 2022Article
- Potential of the Liquid Fermentation of Fishery Waste byPolymers · 2022Article
- Valorization of Side Stream Products from Sea Cage Fattened Bluefin Tuna (Marine drugs · 2022Article
- Exploring Marine as a Rich Source of Bioactive Peptides: Challenges and Opportunities from Marine Pharmacology.Marine drugs · 2022Review
- Astaxanthin from Crustaceans and Their Byproducts: A Bioactive Metabolite Candidate for Therapeutic Application.Marine drugs · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-edible parts of crustaceans could be a rich source of valuable bioactive compounds such as the carotenoid astaxanthin and peptides, which have well-recognized beneficial effects. These compounds are widely used in nutraceuticals and pharmaceuticals, and their market is rapidly growing, suggesting the need to find alternative sources. The aim of this work was to set up a pilot-scale protocol for the reutilization of by-products of processed shrimp, in order to address the utilization of this valuable biomass for nutraceutical and pharmaceuticals application, through the extraction of astaxanthin-enriched oil and antioxidant-rich protein hydrolysates. Astaxanthin (AST) was obtained using "green extraction methods," such as using fish oil and different fatty acid ethyl esters as solvents and through supercritical fluid extraction (SFE), whereas bioactive peptides were obtained by protease hydrolysis. Both astaxanthin and bioactive peptides exhibited bioactive properties in vitro in cellular model systems, such as antioxidant and angiotensin I converting enzyme (ACE) inhibitory activities (IA). The results show higher astaxanthin yields in ethyl esters fatty acids (TFA) extraction and significant enrichment by short-path distillation (SPD) up to 114.80 ± 1.23 µg/mL. Peptide fractions of <3 kDa and 3-5 kDa exhibited greater antioxidant activity while the fraction 5-10 kDa exhibited a better ACE-IA. Lower-molecular-weight bioactive peptides and astaxanthin extracted using supercritical fluids showed protective effects against oxidative damage in 142BR and in 3T3 cell lines. These results suggest that "green" extraction methods allow us to obtain high-quality bioactive compounds from large volumes of shrimp waste for nutraceutical and pharmaceutical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.